Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. is a high-tech enterprise located in the national-level development zone — Hangzhou Economic and Technological Development Zone. The Alltest Biotech campus covers an area of 25 mu, with existing factory and office space of 26,000 square meters. The company's main business is the research, production, and sales of in vitro diagnostic reagents. Its leading products are in the fields of immunodiagnostics, biochemical analysis, and fluorescence, including series related to women's health, infectious diseases, drug abuse, tumors, and cardiovascular health. The company has more than 800 products, many of which have obtained registration and certification from the EU CE, U.S. FDA, Health Canada, Australian TGA, and Brazil Anvisa, and are sold in over 150 countries and regions worldwide. Strong technical research and development and innovation capabilities are a major feature of Alltest Biotech. To date, the company has been granted 59 patents (including 17 invention patents, 23 utility model patents, and 19 design patents), with several more patents currently in the application process. From 2015 to 2019, the company launched more than 100 products cumulatively. Alltest places great emphasis on quality management and has been continuously improving its quality system since its establishment. It has passed inspections such as Korea GMP, and in January 2018, Alltest passed the U.S. FDA inspection with zero deficiencies. In 2018, it also applied for and passed the MDSAP certification recognized by multiple countries, including the United States, Canada, Brazil, Japan, and Australia, becoming one of the earliest companies in China to pass this certification.